Prognostic significance of syndecan-1 expression in human endometrial cancer

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1109-1115

  Hasengaowa, ^a   Kodama, J ^a   Kusumoto, T ^a   Shinyo, Y ^a   Seki, N ^a   Hiramatsu, Y ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Endometrial cancer; Prognosis; Syndecan 1

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; PACLITAXEL; PIRARUBICIN; SYNDECAN 1; MEMBRANE PROTEIN; PROTEOGLYCAN; SDC1 PROTEIN, HUMAN; SYNDECAN;

ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CANCER; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GROWTH; UTERINE CERVIX CANCER; ENDOMETRIUM TUMOR; METABOLISM; MIDDLE AGED; SURVIVAL;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROGNOSIS; PROTEOGLYCANS; STROMAL CELLS; SURVIVAL ANALYSIS; SYNDECAN-1; SYNDECANS;

EID: 25444495294     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi224     Document Type: Article

References (28)

1. Bernfield M, Gotte M, Park PW et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777.
2. Yanagishita M, Hascall VC. Cell surface heparan sulfate proteoglycans. J Biol Chem 1992; 267: 9451-9454.
3. Carey D. Syndecans: Multifunctional cell-surface corecepters. Biochem J 1997; 327: 1-16.
4. Bernfield M, Kokenyesi R, Kato M et al. Biology of syndecans. Annu Rev Cell Biol 1992; 8: 365-393.
5. Sanderson RD, Hinkes M, Bernfield M. Syndecan-1, a cell surface proteoglycan, changes in size and abundance when keratinocytes stratify. J Invest Dermatol 1992; 99: 390-396.
6. Liebersbach BF, Sanderson RD. Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 1994; 269: 20013-20019.
7. Leppa S, Mali M, Miettinen HM, Jalkanen M. Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. Proc Natl Acad Sci USA 1992; 89: 932-936.
8. Inki P, Stenback F, Talve L, Lakanen M. Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation. Am J Pathol 1991; 139: 1333-1340.
9. David JC. Syndecans: Multifunctional cell-surface co-receptors. Biochem J 1997; 327: 1-16.
10. Fujiya M, Watari J, Ashida T et al. Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 2001; 92: 1074-1081.
11. Wiksten JP, Lundin J, Nordling S et al. Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 2001; 95: 1-6.
12. Anttonen A, Kajanti M, Heikkila P et al. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer 1999; 79: 558-564.
13. Klatka J. Syndecan-1 expression in laryngeal cancer. Eur Arch Otorhinolaryngol 2002; 259: 115-118.
14. Stah L, Walter KL, Borczuk AC et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 2004; 101: 1632-1638.
15. Harada K, Masuda S, Hirano M, Nakanuma Y. Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol 2003; 34: 857-863.
16. Kumar-Singh S, Jacobs W, Dhaene K et al. Syndecan-1 expression in malignant mesothelioma: Correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 1998; 186: 300-305.
17. Barbareschi M, Maisonneuve P, Aldovini D et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003; 98: 474-483.
18. Leivonen M, Lundin J, Nordling S et al. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004; 67: 11-18.
19. Davies EJ, Blackball FH, Shanks JH et al. Distribution and clinical significance of heparin sulfate proteoglycans in ovarian cancer. Clin Cancer Res 2004; 10: 5178-5186.
20. Ruoslahti E. Integrins. J Clin Oncol 1991; 87: 1-5.
21. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-1455.
22. Wight T, Kinsella MG, Qwarnstrom EE. The role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 1992; 4: 793-801.
23. Miturski R, Jalkanen M, Postawski K et al. Immunohistochemical expression of syndecan-1 in human endometrial cancer cells. Int J Mol Med 1998; 2: 397-401.
24. Matsumoto A, Ono M, Fujimoto Y et al. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 1997; 74: 482-491.
25. Kato M, Saunders S, Nguyen H, Bernfield M. Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 1995; 6: 559-576.
26. Stanley MJ, Staley MW, Sanderson RD, Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 1999; 112: 377-383.
27. Mukunyadzi P, Liu K, Hanna EY et al. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol 2003; 16: 796-801.
28. Maeda T, Alexander CM, Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cell. Cancer Res 2004; 64: 612-621.